NCT07009548View on ClinicalTrials.gov

CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 26, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Cytomegalovirus (CMV) Infection
Interventions
DRUG

Cytogam

CytoGam 150 mg/kg intravenously (IV) administered as a single dose

Trial Locations (1)

15213

UPMC Presbyterian, Pittsburgh

All Listed Sponsors
collaborator

Kamada, Ltd.

INDUSTRY

lead

Fernanda P Silveira, MD, MS

OTHER